Essential Monitoring of the Office of National Drug Control Policy Updates
Independent Agency
Document Statistics
Documents by Year
Documents by Type (All Time)
Understanding the Role of the Office of National Drug Control Policy
The Office of National Drug Control Policy (ONDCP), part of the Executive Office of the President, is pivotal in shaping and executing the National Drug Control Strategy. Established by the Anti-Drug Abuse Act of 1988, it aims to curb the use, manufacturing, and trafficking of illicit drugs and reduce drug-related crime and health issues.
Key Functions of ONDCP
The ONDCP is tasked with:
- Developing the National Drug Control Strategy to direct anti-drug efforts.
- Establishing a unified drug control program and budget.
- Coordinating federal, state, and local anti-drug activities.
- Advising the President on policy changes to enhance the nation’s anti-drug strategies.
Why Monitoring ONDCP Matters
Compliance Officers, Legal Teams, Policy Analysts, and Healthcare Administrators need to stay informed about ONDCP updates to effectively respond to regulatory changes and strategic shifts. Monitoring ONDCP announcements in the Federal Register is crucial for several reasons:
-
Seizing Funding Opportunities: Certain ONDCP initiatives may open lucrative grants or funding opportunities pertinent to public health organizations, research institutions, and community programs fighting drug abuse.
-
Participating in Comment Periods and Policy Formation: Professionals can actively engage during public comment periods, influencing policy and ensuring strategic alignment with national standards.
-
Adapting to Regulatory Changes: Legal and compliance teams must be prepared for alterations in drug control policies that could impact operational procedures, legal requirements, and compliance frameworks across various sectors.
-
Mitigating Risks: Understanding upcoming changes allows organizations to preemptively address potential risks and ensure they adhere to new regulations, thus avoiding legal penalties.
Industries That Benefit from ONDCP Monitoring
Here are some industries that significantly benefit from monitoring ONDCP updates:
- Healthcare Providers: Navigating regulations to deliver patients services in compliance with federal drug policies.
- Pharmaceutical Companies: Staying ahead of regulatory changes affecting drug manufacturing and distribution.
- Insurance Providers: Aligning policy terms with new drug regulations to mitigate financial and legal risks.
- Education and Research Institutions: Leveraging grants and funding opportunities to conduct anti-drug research and education programs.
- Law Enforcement Agencies: Ensuring policies and operations comply with the updated national anti-drug strategy.
Enhance Your Monitoring with FedMonitor
To successfully track these critical updates, access to robust monitoring tools like FedMonitor can be a game-changer. Our AI-powered platform ensures:
- Relevance Filtering: Receive alerts only on ONDCP issues that matter to you, eliminating information overload.
- Quick Identification of Critical Documents: Easily pinpoint relevant rules, notices, or potential changes affecting your sector.
- Real-Time Notifications: Stay informed through integrations with Slack, Microsoft Teams, Salesforce, as well as SMS and email alerts to catch crucial updates as they happen.
To explore how FedMonitor can support your organizational needs, visit our signup page or contact us for more details.
Agency Details
-
Status:
Active
The Office of National Drug Control Policy (ONDCP) is a functioning component of the Executive Office of the President, responsible for establishing and overseeing the national drug control strategy. Its active role in coordinating drug-related policies and advising the President indicates it is currently operational and functional.
- Acronym: ONDCP
Latest Documents
Title | Type | Published |
---|---|---|
The following persons have been appointed to the ONDCP Senior Executive Service Performance Review Board: Ms. Martha Gagn[eacute] (as Chair), Ms. Debbie Seguin, Ms. Tilda Farhat, and Ms. Kelly George.
|
Notice | Mar 06, 2025 |
The Director of the Office of National Drug Control Policy designated five additional areas as HIDTAs.
|
Notice | Oct 28, 2024 |
The following persons have been appointed to the ONDCP Senior Executive Service Performance Review Board: Ms. Martha Gagn[eacute] (as Chair), Mr. Kemp Chester, Shannon Kelly and Ms. Michele Marx.
|
Notice | Jul 26, 2024 |
Pursuant to the Privacy Act of 1974, the Office of National Drug Control Policy (ONDCP), proposes to establish a new system of records entitled "Correspondence Management systems (CMS) for the Office of National Drug Control Policy (ONDCP)", ONDCP/00...
|
Notice | Jan 18, 2024 |
In accordance with the Paperwork Reduction Act of 1995, the Office of National Drug Control Policy (ONDCP) announces it will submit to the Office of Management and Budget (OMB) Office of Information and Regulatory Affairs (OIRA) an information collec...
|
Notice | Sep 28, 2022 |
Notice is hereby given of the names of members of the Office of National Drug Control Policy (ONDCP) Performance Review Board (PRB). The members of the PRB for ONDCP are: Ms. Martha Gagn[eacute] (as Chair), Mr. David Holtgrave, Mr. Eric Talbot, and M...
|
Notice | Aug 22, 2022 |
The Director of the Office of National Drug Control Policy designated six additional areas as High Intensity Drug Trafficking Areas (HIDTA). See SUPPLEMENTARY INFORMATION for locations.
|
Notice | Jul 27, 2022 |
In accordance with the Paperwork Reduction Act of 1995, the Office of National Drug Control Policy (ONDCP) announces it will submit to the Office of Management and Budget (OMB) Office of Information and Regulatory Affairs (OIRA) an information collec...
|
Notice | Jun 23, 2022 |
The following persons have been appointed to the ONDCP Senior Executive Service Performance Review Board: Ms. Martha Gagn[eacute] (as Chair), Mr. Kemp Chester, Mr. Eric Talbot, and Ms. Michele Marx.
|
Notice | Jul 29, 2021 |
The Office of National Drug Control Policy (ONDCP) is seeking comments from the public on whether and to what extent ONDCP's policy development process, drug budget review and certification processes of the 18 National Drug Control Program Agencies,...
|
Notice | Jul 07, 2021 |
The Director of the Office of National Drug Control Policy designated six additional areas as High Intensity Drug Trafficking Areas (HIDTA).. The new areas are (1) Daviess County in Kentucky as part of the Appalachia HIDTA; (2) El Dorado and Placer C...
|
Notice | May 24, 2021 |
The Office of National Drug Control Policy (ONDCP) is updating its Freedom of Information Act (FOIA) implementing regulation to comport with the FOIA Improvement Act of 2016 and best practices. The final rule describes how to make a FOIA request with...
|
Rule | Oct 16, 2020 |
The following persons have been appointed to the ONDCP Senior Executive Service Performance Review Board: Ms. Martha Gagn[eacute] (as Chair), Mr. Kemp Chester, Mr. Eric Talbot, and Dr. Terry Zobeck.
|
Notice | Jul 17, 2020 |
The Director of the Office of National Drug Control Policy designated 3 additional areas as High Intensity Drug Trafficking Areas (HIDTA).
|
Notice | Jun 11, 2020 |
The Director of the Office of National Drug Control Policy designated 12 additional areas as High Intensity Drug Trafficking Areas (HIDTA) pursuant to 21 U.S.C. 1706(b)(1). The new areas are (1) Davidson County in Tennessee as part of the Appalachia...
|
Notice | Jun 04, 2020 |
The Office of National Drug Control Policy (ONDCP) is updating its Freedom of Information Act (FOIA) implementing regulation to comport with the FOIA Improvement Act of 2016 and best practices. The proposed rule describes how to make a FOIA request w...
|
Proposed Rule | May 22, 2020 |
The Office of National Drug Control Policy is announcing this Advance Notice of Proposed Rulemaking (ANPRM) and requests information relevant to criteria for designating and terminating the designation of emerging drug threats in the United States pu...
|
Proposed Rule | May 15, 2020 |
The Office of National Drug Control Policy published a document in the Federal Register on December 12, 2019 concerning the Paperwork Reduction Act; Proposed Collection; Comment Request. The document contained an incorrect address and contact informa...
|
Notice | Dec 26, 2019 |
The Office of National Drug Control Policy published a document in the Federal Register on December 12, 2019 concerning the Paperwork Reduction Act; Proposed Collection; Comment Request. The document contained an incorrect address and contact informa...
|
Notice | Dec 26, 2019 |
In accordance with the Paperwork Reduction Act of 1995, the Office of National Drug Control Policy (ONDCP) announces it will submit to the Office of Management and Budget (OMB) and Office of Information and Regulatory Affairs (OIRA) an information co...
|
Notice | Dec 12, 2019 |
No sub-agencies found.